Source:http://linkedlifedata.com/resource/pubmed/id/17898884
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2007-9-27
|
pubmed:abstractText |
Leishmaniasis represents a complex of diseases with an important clinical and epidemiological diversity. Visceral leishmaniasis is of higher priority than cutaneous leishmaniasis as it is a fatal disease in the absence of treatment. The clinical spectrum of leishmaniasis and control of the infection are influenced by the parasite-host relationship. The role of cellular immune responses of the Th1 type in the protection against disease in experimental and human leishmaniasis is well established. TNF-alpha has been implicated in cytokine-induced macrophage activation and tissue granuloma formation, two activities linked to control of intracellular visceral infection caused by Leishmania donovani. Anti-tumor necrosis factor-alpha (TNF-alpha) strategies have had a marked and substantial impact in the treatment of rheumatoid arthritis, however the clinical use of TNF-alpha antagonists has been accompanied by increased reporting of infections. Here we report the first case of visceral leishmaniasis in a patient treated for a long period of time with human anti TNF-alpha monoclonal antibody, adalimumab. Due to the low incidence rate of Mediterranean visceral leishmaniasis, a systematic screening for leishmaniasis in all patients treated with biologics may be not recommended. However, for those patients living at high risk of leishmaniasis exposure, a periodical serological monitoring should be performed during therapy with anti-TNF monoclonal antibodies.
|
pubmed:language |
ita
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/adalimumab
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0048-7449
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
59
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
235-9
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:17898884-Aged,
pubmed-meshheading:17898884-Animals,
pubmed-meshheading:17898884-Antibodies, Monoclonal,
pubmed-meshheading:17898884-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17898884-Arthritis, Rheumatoid,
pubmed-meshheading:17898884-Combined Modality Therapy,
pubmed-meshheading:17898884-Female,
pubmed-meshheading:17898884-Humans,
pubmed-meshheading:17898884-Immunocompromised Host,
pubmed-meshheading:17898884-Immunosuppressive Agents,
pubmed-meshheading:17898884-Immunotherapy,
pubmed-meshheading:17898884-Italy,
pubmed-meshheading:17898884-Leishmania donovani,
pubmed-meshheading:17898884-Leishmaniasis, Visceral,
pubmed-meshheading:17898884-Methotrexate,
pubmed-meshheading:17898884-Th1 Cells,
pubmed-meshheading:17898884-Tumor Necrosis Factor-alpha
|
pubmed:articleTitle |
[Leishmaniasis in rheumatoid arthritis].
|
pubmed:affiliation |
U.O. Clinica Reumatologica, Dipartimento di Medicina Interna Università di Genova, Genova, Italia. carmenpizzorni@virgilio.it
|
pubmed:publicationType |
Journal Article,
English Abstract,
Review,
Case Reports
|